Bloomberg recently reported that pharmaceutical company Novo Nordisk (NYSE:NVO), in collaboration with a small biotech company called Merrion Pharmaceuticals, recently completed a phase 1 study for an oral insulin drug. The experimental medication, known only as NN1954, could help the company's revenue grow over the long term if it eventually gains approval. However, Motley Fool health care analyst Max Macaluso believes that investors shouldn't get too excited about this news just yet. Watch the following video to find out why and how Novo Nordisk's project may one day become a threat to Sanofi's (NYSE:SNY) mega-blockbuster insulin drug Lantus.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.